NEJM 29 Aug-12 Sep 2013 Vol 369 799 When comparing a new fixed-dose anticoagulant with conventional warfarin based anticoagulation, what do you look for? Thrombotic events, death, major bleeding? Yes, certainly. But what makes the comparison meaningful? That depends largely on how well the warfarin group were kept within the target INR range. In the […]
Richard Lehman’s journal review—16 September 2013